Bicara Therapeutics (BCAX) Insider Trading & Ownership $9.07 -0.13 (-1.37%) Closing price 07/3/2025 01:34 PM EasternExtended Trading$9.17 +0.10 (+1.10%) As of 07/3/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock Bicara Therapeutics (NASDAQ:BCAX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage15.50%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)$34.25MNumber OfInsiders Selling(Last 12 Months)0 Get BCAX Insider Trade Alerts Want to know when executives and insiders are buying or selling Bicara Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address BCAX Insider Buying and Selling by Quarter Bicara Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/17/2024James E FlynnMajor ShareholderBuy70,000$18.00$1,260,000.00 9/16/2024Ra Capital Management, L.P.DirectorBuy1,833,000$18.00$32,994,000.00 (Data available from 1/1/2013 forward) BCAX Insider Trading Activity - Frequently Asked Questions Who is on Bicara Therapeutics' Insider Roster? The list of insiders at Bicara Therapeutics includes James E Flynn, and Ra Capital Management, L.P.. Learn more on insiders at BCAX. What percentage of Bicara Therapeutics stock is owned by insiders? 15.50% of Bicara Therapeutics stock is owned by insiders. Learn more on BCAX's insider holdings. Which Bicara Therapeutics insiders have been buying company stock? The following insiders have purchased BCAX shares in the last 24 months: James E Flynn ($1,260,000.00), and Ra Capital Management, L.P. ($32,994,000.00). How much insider buying is happening at Bicara Therapeutics? Insiders have purchased a total of 1,903,000 BCAX shares in the last 24 months for a total of $34,254,000.00 bought. Bicara Therapeutics Key ExecutivesMs. Claire Mazumdar Clemon M.B.A. (Age 35)Ph.D., CEO & Director Compensation: $650kMr. Ryan Cohlhepp Pharm.D. (Age 48)President, COO & Director Compensation: $660kMr. Ivan Hyep M.B.A. (Age 40)Chief Financial Officer Compensation: $597.5kMs. Lara S. Meisner J.D. (Age 52)Chief Legal Officer & Corporate Secretary Ms. Rachel SalazarSVP of R&D Strategy and OperationsMs. Sathish Hasige Ph.D.Senior VP and Head of Technical Operations & Supply ChainDr. David Raben M.D. (Age 61)Chief Medical Officer Ms. Angela WindtVP & Head of Regulatory AffairsDr. Jeltje Schulten M.B.A.M.D., Senior Vice President of Clinical & Medical AffairsMr. Jean-Paul RodriqueSenior Vice President of Quality More Insider Trading Tools from MarketBeat Related Companies DNLI Insider Buying NAMS Insider Buying AGIO Insider Buying SRPT Insider Buying CGON Insider Buying APGE Insider Buying IDYA Insider Buying HRMY Insider Buying IRON Insider Buying TARS Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insider Selling at NVIDIA Could Turn Into an Opportunity The Top Insider Sells From Q2: Buy, Sell, or Hold?3 Hot Trades for Insiders, But Are They Good Buys for Investors?Insiders Chase Income and Stability in American Tower—Here’s Why3 Tech Stocks With High and Rising Institutional Interest This page (NASDAQ:BCAX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
